Cargando…
Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the tim...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000528/ https://www.ncbi.nlm.nih.gov/pubmed/32064265 http://dx.doi.org/10.3389/fmed.2020.00008 |
_version_ | 1783494061890469888 |
---|---|
author | Cornish, Jack S. Wirthgen, Elisa Däbritz, Jan |
author_facet | Cornish, Jack S. Wirthgen, Elisa Däbritz, Jan |
author_sort | Cornish, Jack S. |
collection | PubMed |
description | The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the time from active disease to clinical remission and mucosal healing. The prospect of such individualized treatment of IBD would be aided by accurate biomarkers, both fecal and serological, which have to date shown value as indicators of IBD activity. Here we review the utility of generic biomarkers for inflammation or mucosal healing, such as calprotectin, C-reactive protein (CRP), and fecal hemoglobin (fHb) as predictors of response to treatment of IBD. We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine. |
format | Online Article Text |
id | pubmed-7000528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70005282020-02-14 Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease Cornish, Jack S. Wirthgen, Elisa Däbritz, Jan Front Med (Lausanne) Medicine The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the time from active disease to clinical remission and mucosal healing. The prospect of such individualized treatment of IBD would be aided by accurate biomarkers, both fecal and serological, which have to date shown value as indicators of IBD activity. Here we review the utility of generic biomarkers for inflammation or mucosal healing, such as calprotectin, C-reactive protein (CRP), and fecal hemoglobin (fHb) as predictors of response to treatment of IBD. We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine. Frontiers Media S.A. 2020-01-29 /pmc/articles/PMC7000528/ /pubmed/32064265 http://dx.doi.org/10.3389/fmed.2020.00008 Text en Copyright © 2020 Cornish, Wirthgen and Däbritz. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cornish, Jack S. Wirthgen, Elisa Däbritz, Jan Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title | Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title_full | Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title_fullStr | Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title_full_unstemmed | Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title_short | Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease |
title_sort | biomarkers predictive of response to thiopurine therapy in inflammatory bowel disease |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000528/ https://www.ncbi.nlm.nih.gov/pubmed/32064265 http://dx.doi.org/10.3389/fmed.2020.00008 |
work_keys_str_mv | AT cornishjacks biomarkerspredictiveofresponsetothiopurinetherapyininflammatoryboweldisease AT wirthgenelisa biomarkerspredictiveofresponsetothiopurinetherapyininflammatoryboweldisease AT dabritzjan biomarkerspredictiveofresponsetothiopurinetherapyininflammatoryboweldisease |